TB symptom screening and treatment cascade among adults receiving HIV care in Uganda: a secondary analysis of the Uganda Population-Based HIV Impact Assessment (UPHIA) 2020–2021

People living with HIV (PLHIV) face a disproportionate tuberculosis (TB) burden. WHO recommends routine four-symptom TB screening at every HIV care visit. However, how well this recommendation translates into completed diagnostic evaluation and treatment in Uganda has not been comprehensively described using nationally representative data. We aimed to determine the prevalence and factors associated with a positive TB symptom screen and TB preventive therapy (TPT) uptake among PLHIV in HIV care. We conducted a secondary analysis of the Uganda Population-Based HIV Impact Assessment (UPHIA) 2020–2021, a nationally representative household survey. The analytic sample comprised PLHIV with a valid TB symptom screening result at their last HIV care visit. A positive TB symptom screen was defined as self-reported cough, fever, night sweats, or weight loss at that visit, and TPT uptake as self-reported ever having taken medicine to prevent TB. Factors associated with a positive screen and with TB preventive therapy uptake were examined using modified Poisson regression with jackknife variance, adjusted a priori for age, sex, residence, and region. A p < 0.05 was considered statistically significant. The weighted prevalence of a positive TB symptom screen was 59.3% (95% CI 56.2–62.4; 673/1,116 participants unweighted). In adjusted models, only region was independently associated with a positive screen, with higher prevalence in Mid North (adjusted prevalence ratio [aPR] 1.20, 95% CI 1.01–1.43, p = 0.040) and Northeast: Karamoja (aPR 1.29, 95% CI 1.01–1.65, p = 0.042) relative to Central 1: South Buganda. Of the 673 symptom-positive participants, 162 (weighted 26.2%, 95% CI 22.7–30.0) had a clinic visit, and 34 of the 161 with a recorded diagnostic outcome (weighted 22.4%, 95% CI 16.7–29.4) were diagnosed with TB. The weighted prevalence of TPT uptake among eligible PLHIV was 60.7% (95% CI 57.2–64.2; 652/1,072 unweighted), with modestly higher adjusted prevalence in Central 2: North Buganda relative to Central 1 (aPR 1.25, 95% CI 1.05–1.48, p = 0.012). TB symptom screening reaches most PLHIV in HIV care and identifies a substantial proportion as symptom-positive, but fewer than a third of these receive documented follow-up evaluation, and only a minority of those evaluated are ultimately diagnosed with TB. Strengthening referral and follow-through after a positive screen, and understanding the modest regional variation observed in TB preventive therapy uptake, are concrete targets for programmatic attention.

Authors

Institutions

Publication Details

Journal
BMC Infectious Diseases
Published
2026-11-14
DOI
https://doi.org/10.1186/s12879-026-14854-7
Primary Topic
Tuberculosis Research and Epidemiology
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

TB symptom screening and treatment cascade among adults receiving HIV care in Uganda: a secondary analysis of the Uganda Population-Based HIV Impact Assessment (UPHIA) 2020–2021

Donald Otika, Brenda Lalam, Morrish Obol Okello, Ahmed Jelle et al.
BMC Infectious Diseases
Tuberculosis Research and Epidemiology
article

TB symptom screening and treatment cascade among adults receiving HIV care in Uganda: a secondary analysis of the Uganda Population-Based HIV Impact Assessment (UPHIA) 2020–2021

Donald Otika, Brenda Lalam, Morrish Obol Okello, Ahmed Jelle, Samira Muhyadin Shide, Kalthun Ali, Hilal Ibrahim, Abdirahman Gedi Abdi, Amina Bashe Ali
article en

Abstract

People living with HIV (PLHIV) face a disproportionate tuberculosis (TB) burden. WHO recommends routine four-symptom TB screening at every HIV care visit. However, how well this recommendation translates into completed diagnostic evaluation and treatment in Uganda has not been comprehensively described using nationally representative data. We aimed to determine the prevalence and factors associated with a positive TB symptom screen and TB preventive therapy (TPT) uptake among PLHIV in HIV care. We conducted a secondary analysis of the Uganda Population-Based HIV Impact Assessment (UPHIA) 2020–2021, a nationally representative household survey. The analytic sample comprised PLHIV with a valid TB symptom screening result at their last HIV care visit. A positive TB symptom screen was defined as self-reported cough, fever, night sweats, or weight loss at that visit, and TPT uptake as self-reported ever having taken medicine to prevent TB. Factors associated with a positive screen and with TB preventive therapy uptake were examined using modified Poisson regression with jackknife variance, adjusted a priori for age, sex, residence, and region. A p < 0.05 was considered statistically significant. The weighted prevalence of a positive TB symptom screen was 59.3% (95% CI 56.2–62.4; 673/1,116 participants unweighted). In adjusted models, only region was independently associated with a positive screen, with higher prevalence in Mid North (adjusted prevalence ratio [aPR] 1.20, 95% CI 1.01–1.43, p = 0.040) and Northeast: Karamoja (aPR 1.29, 95% CI 1.01–1.65, p = 0.042) relative to Central 1: South Buganda. Of the 673 symptom-positive participants, 162 (weighted 26.2%, 95% CI 22.7–30.0) had a clinic visit, and 34 of the 161 with a recorded diagnostic outcome (weighted 22.4%, 95% CI 16.7–29.4) were diagnosed with TB. The weighted prevalence of TPT uptake among eligible PLHIV was 60.7% (95% CI 57.2–64.2; 652/1,072 unweighted), with modestly higher adjusted prevalence in Central 2: North Buganda relative to Central 1 (aPR 1.25, 95% CI 1.05–1.48, p = 0.012). TB symptom screening reaches most PLHIV in HIV care and identifies a substantial proportion as symptom-positive, but fewer than a third of these receive documented follow-up evaluation, and only a minority of those evaluated are ultimately diagnosed with TB. Strengthening referral and follow-through after a positive screen, and understanding the modest regional variation observed in TB preventive therapy uptake, are concrete targets for programmatic attention.

BMC Infectious Diseases
The AIDS Support Organization (UG), Gulu University (UG), Islamic University in Uganda (UG), Uganda Cancer Institute (UG), Soroti University (UG)
Tuberculosis Research and Epidemiology
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon